Business
Licence Agreement with GHFG Ltd.
Licence Agreement with GHFG Ltd..
About this update from Clean Power Hydrogen Plc
[{"type":"text","content":"\n \n \n \n \n \n The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which is part of UK law by virtue of the European Union (withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.\n \n \n \n \n \n \n \n \n \n \n \n 19 July 2022\n \n \n \n \n \n \n \n \n \n Clean Power Hydrogen Plc\n \n \n \n \n (\"CPH2\", the \"Company\" or the \"Group\")\n \n \n \n \n \n \n \n \n \n Licence Agreement with GHFG Ltd.\n \n \n \n \n \n \n CPH2, the UK-based green hydrogen technology and manufacturing company that has developed the IP-protected Membrane-Free Electrolyser (\"MFE\"), is pleased to announce that it has signed its first licence agreement with GHFG Ltd (\"GHFG\") for the construction of 2 gigawatts (\"GW\") of MFE electrolysers over a period of up to 20 years.\n \n \n \n \n \n GHFG is a joint venture between international renewable independent power producer, Alternus Energy Group Plc (\"Alternus\"), and Eric Whelan, CEO of Irish based developer, Soleirtricity. Under the licence agreement, GHFB will produce the CPH2 MFE electrolysers at a new facility in Ireland and plans to start production during 2023. Each electrolyser produced by GHFG under this agreement will be installed alongside and powered from solar energy projects owned and operated by Alternus.\n \n \n \n \n \n Under the agreement, CPH2 will receive an upfront licence fee, and thereafter, a technology fee per unit, followed by service and maintenance licences during the unit's life. The upfront licence fee is expected to be received in full by the end of the current financial year and to be recognised as revenue over the life of the contract.\n \n \n \n \n \n The licensing of the CPH2 proprietary technology offers the Company the potential to significantly increase revenue in the short term without the need for additional capital expenditure. Given the business model's potential low cost and short lead time, the Directors believe it is an ideal opportunity to establish market share and improve market penetration on a global basis by using the high margin, low capex licencing strategy to fund further R&D.\n \n \n \n \...